FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025574413> ?p ?o ?g. }

• W2025574413 endingPage "94" @default.
• W2025574413 startingPage "89" @default.
• W2025574413 abstract "Williams C. Tamoxifen in related ovarian cancer: A systematic review. Int J Gynecol Cancer 1998; 8: 89–94.This review examines the evidence for useful clinical activity of tamoxifen in women with ovarian carcinoma who have failed conventional cytotoxic chemotherapy.The optimized search strategy of the Cochrane Gynaecological Cancer Collaborative Review Group, together with citations provided by Zeneca (the manufacturer of tamoxifen), and authors of trials identified in this area were used. Selection criteria consisted of phase 2 trials, randomized or unrandomized, of tamoxifen in women with ovarian carcinoma, previously treated with cytotoxic chemotherapy. Phase 3 trials in similar patients were also sought. Trials were then assessed for inclusion in the study and data extracted by the author.There are no randomized controlled trials of tamoxifen alone vs best supportive care in patients with refractory or recurrent ovarian cancer. There is a series of phase 2 trials that report objective response rates and (in some) stable disease rates. Fifty-five of 503 patients (10.9%) were reported to have achieved an objective response and 59 of 291 patients (24%) achieved stable disease (for variable periods). Since only a subset of trials reported rates of stable disease, these may form a biased group favoring a high rate of disease stabilization. There were no analyzable data on duration of response or overall survival. There were no useful data presented on the palliative effects of tamoxifen, in terms of symptom control or quality of life.Tamoxifen demonstrates a modest degree of effectiveness in ovarian cancer refractory to cytotoxic chemotherapy. The overall objective response rate in all trials (503 patients) was about 11%. There is, however, a wide variation in the objective response rates in the different trials (0% to 56%). This may, in part, reflect varying criteria for selection of patients for inclusion in individual studies and different methods for recording responses and application of these methods. Some trials reported on rates of stabilization of disease, but these data may be biased as such information was only presented in selected studies. There is no useful analyzable data on the duration of responses or survival. There is also, importantly, virtually no data on the palliative effects of tamoxifen given in this situation, even though the intent of treatment was entirely palliative. Those studies that collected data on hormone receptors found no consistent correlation between the presence of receptors and an increased chance of response to tamoxifen." @default.
• W2025574413 created "2016-06-24" @default.
• W2025574413 creator A5088973528 @default.
• W2025574413 date "1998-03-01" @default.
• W2025574413 modified "2023-09-27" @default.
• W2025574413 title "Tamoxifen in relapsed ovarian cancer: A systematic review" @default.
• W2025574413 cites W1969870046 @default.
• W2025574413 cites W1971219491 @default.
• W2025574413 cites W1974841944 @default.
• W2025574413 cites W1975673721 @default.
• W2025574413 cites W1992008068 @default.
• W2025574413 cites W1993711570 @default.
• W2025574413 cites W1997923966 @default.
• W2025574413 cites W2000258537 @default.
• W2025574413 cites W2001446631 @default.
• W2025574413 cites W2004371073 @default.
• W2025574413 cites W2006860223 @default.
• W2025574413 cites W2031962083 @default.
• W2025574413 cites W2035030431 @default.
• W2025574413 cites W2038674422 @default.
• W2025574413 cites W2061368728 @default.
• W2025574413 cites W2075799745 @default.
• W2025574413 cites W2078473351 @default.
• W2025574413 cites W2079961141 @default.
• W2025574413 cites W2082700181 @default.
• W2025574413 cites W2084764784 @default.
• W2025574413 cites W2118229928 @default.
• W2025574413 cites W2134030548 @default.
• W2025574413 cites W2313472714 @default.
• W2025574413 cites W4210704032 @default.
• W2025574413 doi "https://doi.org/10.1046/j.1525-1438.1998.09828.x" @default.
• W2025574413 hasPublicationYear "1998" @default.
• W2025574413 type Work @default.
• W2025574413 sameAs 2025574413 @default.
• W2025574413 citedByCount "15" @default.
• W2025574413 countsByYear W20255744132015 @default.
• W2025574413 countsByYear W20255744132022 @default.
• W2025574413 crossrefType "journal-article" @default.
• W2025574413 hasAuthorship W2025574413A5088973528 @default.
• W2025574413 hasConcept C121608353 @default.
• W2025574413 hasConcept C126322002 @default.
• W2025574413 hasConcept C143998085 @default.
• W2025574413 hasConcept C2777176818 @default.
• W2025574413 hasConcept C2780427987 @default.
• W2025574413 hasConcept C29456083 @default.
• W2025574413 hasConcept C530470458 @default.
• W2025574413 hasConcept C71924100 @default.
• W2025574413 hasConceptScore W2025574413C121608353 @default.
• W2025574413 hasConceptScore W2025574413C126322002 @default.
• W2025574413 hasConceptScore W2025574413C143998085 @default.
• W2025574413 hasConceptScore W2025574413C2777176818 @default.
• W2025574413 hasConceptScore W2025574413C2780427987 @default.
• W2025574413 hasConceptScore W2025574413C29456083 @default.
• W2025574413 hasConceptScore W2025574413C530470458 @default.
• W2025574413 hasConceptScore W2025574413C71924100 @default.
• W2025574413 hasIssue "2" @default.
• W2025574413 hasLocation W20255744131 @default.
• W2025574413 hasOpenAccess W2025574413 @default.
• W2025574413 hasPrimaryLocation W20255744131 @default.
• W2025574413 hasRelatedWork W2013375884 @default.
• W2025574413 hasRelatedWork W2025574413 @default.
• W2025574413 hasRelatedWork W2069482181 @default.
• W2025574413 hasRelatedWork W2091020218 @default.
• W2025574413 hasRelatedWork W2130755392 @default.
• W2025574413 hasRelatedWork W2353260778 @default.
• W2025574413 hasRelatedWork W2418638721 @default.
• W2025574413 hasRelatedWork W2789448498 @default.
• W2025574413 hasRelatedWork W2948359515 @default.
• W2025574413 hasRelatedWork W3030579031 @default.
• W2025574413 hasVolume "8" @default.
• W2025574413 isParatext "false" @default.
• W2025574413 isRetracted "false" @default.
• W2025574413 magId "2025574413" @default.
• W2025574413 workType "article" @default.